2370-P: Community-Based Early-Stage Type 1 Diabetes Screening in Underserved Populations
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2370-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JASNEET BAJWA und 1 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: Early detection of early-stage T1D improves clinical outcomes and enables interventions that delay disease progression. Yet, screening outside clinical research is limited. Population-based studies report autoantibody (AutoAb) positivity in ~1% of screened individuals, highlighting the need for community-based screening. This study evaluates the feasibility and accessibility of mobile T1D AutoAb screening in the underserved California Counties.
Methods
This ongoing cross-sectional study is conducted through the Mobile Diabetes Education Center (MOBEC), which offers free preventive services at community events. People aged ≥10 years receive pre-screen education and fingerstick-based T1D AutoAb screening (Enable BiosciencesTM). T1D experts review positive results, all participants receive a follow up phone call with the results. Participants with positive tests are referred for confirmatory testing.
Results
To date, 56 individuals participated with a diverse cohort. Three participants (5.4%) had known or suspected diabetes and positive results. The remaining 53 participants (96.4%) screened negative. Participants reported high acceptability and valued accessible, cost-free, community-based screening. Follow up with test results has been challenging in 17% of participants (9/53). Data collection is ongoing.
Conclusion
Mobile community-based T1D AutoAb screening is feasible and reaches underserved populations, supporting equitable early detection and potentially reducing delayed T1D diagnosis and DKA. Disclosure J. Bajwa: None. J. Shubrook: Advisory Panel; Current; Abbott Diabetes. Other - Doc Care Deputy EditorConsensus panel-liver health, screening early stage T1d, Technology in primary care; Current; American Diabetes Association. Advisory Panel; Current; Bayer AG, Boehringer Ingelheim International GmbH. Consultant; Ended; Corcept Therapeutics. Advisory Panel; Ended; Idorsia Pharmaceuticals Ltd. Advisory Panel; Current; Insulet Corporation. Advisory Panel; Ended; Madrigal Pharmaceuticals, Inc. Consultant; Current; Novo Nordisk, Sanofi. Funding Breakthrough T1D-community screening seed grant
Zitieren
APA
BAJWA, J., & SHUBROOK, J. (2026). 2370-P: Community-Based Early-Stage Type 1 Diabetes Screening in Underserved Populations. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2370-p
Vancouver
BAJWA J, SHUBROOK J. 2370-P: Community-Based Early-Stage Type 1 Diabetes Screening in Underserved Populations. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2370-p
BibTeX
@article{BAJWA2026,
author = {BAJWA, JASNEET and SHUBROOK, JAY},
title = {2370-P: Community-Based Early-Stage Type 1 Diabetes Screening in Underserved Populations},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2370-p}
}
EUVIMED